Soleno Therapeutics, Inc. Series A Warrant
SLNOW
SLNOW was delisted on the 8th of November, 2019.
3 hedge funds and large institutions have $297K invested in Soleno Therapeutics, Inc. Series A Warrant in 2018 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
924% more capital invested
Capital invested by funds: $29K → $297K (+$268K)
0% more funds holding
Funds holding: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$100K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
6CM
1
683 Capital Management
New York
| $273K | +$100K | +602,443 | New |
|
|
VC
2
Vivo Capital
Palo Alto,
California
| $23K | – | – | – |
|
3
UBS Group
Zurich,
Switzerland
| $1K | – | – | – |
|
SLNOW Hedge Fund Activity: Q1 2018 in Review
3 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics, Inc. Series A Warrant (SLNOW) for Q1 2018, worth a combined $297K — up 924% from $29K a quarter earlier.
Fund positioning in SLNOW was balanced in Q1 2018: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.
The largest buyer was 683 Capital Management, opening a new position worth an estimated $100K.
- 3 institutional investors held Soleno Therapeutics, Inc. Series A Warrant (SLNOW) as of Q1 2018, unchanged from Q4 2017.
- Funds reported $297K of Soleno Therapeutics, Inc. Series A Warrant stock for Q1 2018, up 924% quarter-over-quarter.
- 1 fund opened new Soleno Therapeutics, Inc. Series A Warrant positions in Q1 2018 and 1 closed out, a net change of 0 holders.
- The largest Soleno Therapeutics, Inc. Series A Warrant buyer in Q1 2018 was 683 Capital Management, an estimated $100K added.
Based on aggregated 13F filings for Q1 2018.